Aptorum Group Ltd

Aptorum Group Limited is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic assets for diseases with unmet medical needs, specifically in oncology (including orphan oncology indications) and infectious diseases. The company's business model is centered on research and development (R&D) of novel and repurposed therapeutics and diagnostics technology across various disease areas, with a strategic emphasis on products that may qualify for orphan drug designation and address unmet medical needs. Aptorum generates revenue through its R&D efforts and aims to expand its portfolio through collaborations with academic institutions and Contract Research Organizations (CROs), leveraging its in-house pharmaceutical development center and management expertise, and securing government grants to fund project development. The company has streamlined its operations by terminating clinic services and suspending non-lead R&D projects to optimize resource allocation and focus on its most promising lead projects.

Aptorum's core business model is currently focused entirely on R&D, having ceased all therapeutic services as of December 31, 2025, and the date of this report. The company generates revenue through its R&D activities and aims to commercialize therapeutic and diagnostic innovations. Its primary customer segments are not explicitly defined as it is in the R&D phase, but its strategy involves seeking collaborative partnerships for clinical development and commercialization. The company's structure includes a Cayman Islands holding company, Aptorum Group Limited, with operations conducted through subsidiaries like Aptorum Therapeutics Limited and Acticule Life Sciences Limited. It also has a Variable Interest Entity (VIE), Libra Sciences Limited, though Aptorum is not deemed its primary beneficiary and thus does not consolidate its financial statements.

The company's detailed product and service line breakdown centers on two Lead Projects: ALS-4 and SACT-1. ALS-4 is a small drug molecule designed to treat bacterial infections caused by Staphylococcus aureus, including Methicillin-resistant Staphylococcus aureus (MRSA), by targeting bacterial virulence expression. Preclinical studies for ALS-4 have shown potent activity against Staphylococcus aureus pigment formation in vitro with an IC50 of 20 nM ¹. In a MRSA wound infection mouse model, oral dosing of ALS-4 at 30mg/kg twice a day demonstrated a statistically significant improvement in wound healing, with 63.8% wound closure compared to 48.4% for oral Linezolid and 43.2% for topical Mupirocin 2% ². In a non-lethal MRSA bacteraemia mouse model, ALS-4 significantly reduced bacterial counts in major organs, and in a lethal MRSA bacteraemia rat model, it showed a 56% survival rate versus 0% for the control group ³. A Phase 1 clinical trial for ALS-4 in 72 healthy subjects has been completed, with no serious adverse events observed ⁴. Aptorum is proceeding towards an Investigational New Drug (IND) submission for ALS-4 targeting Acute Bacterial Skin and Skin Structure Infections (ABSSSI) to initiate a Phase 2 clinical study.

SACT-1 is a repurposed drug candidate developed under the Smart-ACT® drug discovery platform, initially targeting neuroblastoma, a rare orphan cancer predominantly affecting children aged 5 years and below. The 5-year survival rate for high-risk neuroblastoma patients is around 40-50% ⁵. SACT-1 has demonstrated effectiveness against numerous neuroblastoma cell lines, including MYCN-amplified cells, and exhibits high and robust synergism with traditional chemotherapy in vitro ⁶. In a xenograft mouse model of neuroblastoma, SACT-1 combined with standard of care (SOC) chemotherapy resulted in a statistically significant tumor shrinkage of up to 54.2% in the first 22 days compared to the control group (SOC only) ⁷. SACT-1 has received Orphan Drug Designation from the US FDA ⁸ and has completed a Phase 1 clinical trial assessing relative bioavailability and food effect in healthy adult volunteers, with no serious adverse events reported ⁹. The US FDA has generally agreed with the chemistry-manufacturing-control (CMC) strategy and the proposed clinical development plan for SACT-1 Phase 1/2 trials ¹⁰.

For the fiscal year ended December 31, 2025, Aptorum Group Limited reported cash and cash equivalents of $3.5 million ¹¹. The company's current assets were approximately $3.6 million ¹². No revenue from product sales was generated during this period, as the company is in the R&D phase. Specific figures for gross profit, gross margin, operating income, operating margin, net income, basic and diluted EPS, total debt, and net debt are not explicitly provided in the summary sections of the filing for the reported fiscal period.

Year-over-year comparisons are not explicitly detailed with specific figures for revenue growth by segment or margin expansion/contraction, as the company is in the R&D phase and does not generate revenue from product sales. However, the company's cash and cash equivalents increased from $0.9 million as of December 31, 2024, to $3.5 million as of December 31, 2025 ¹³. A significant operational development during the period was the decision in the second quarter of 2023 to streamline operations by terminating clinic services and suspending non-lead R&D projects to focus resources on lead projects. The company also entered into a Merger Agreement with DiamiR on July 14, 2025, to acquire 100% of DiamiR's outstanding shares, with DiamiR stockholders and existing Aptorum shareholders expected to own approximately 70% and 30%, respectively, of the outstanding shares of the Combined Company post-merger ¹⁴. Concurrently, Aptorum Therapeutics entered into a management services agreement and an intellectual property license agreement with DiamiR, with terms extending until the earlier of the merger closing or June 30, 2026.

Management's specific revenue, margin, or EPS guidance for the upcoming period is not explicitly provided in the filing, as the company is in the R&D phase and does not currently generate revenue from product sales. The company's ability to generate revenue and become profitable is dependent on successfully completing the development of its drug candidates, obtaining necessary regulatory approvals, and manufacturing and marketing its drug products.

A major growth area for Aptorum is the advancement of its Lead Projects, ALS-4 and SACT-1. For ALS-4, the company is proceeding towards an IND submission to initiate a Phase 2 clinical study targeting Acute Bacterial Skin and Skin Structure Infections (ABSSSI), following positive feedback from the US FDA on its overall development strategy. For SACT-1, the company has completed an End of Phase 1 (EOP1) meeting with the US FDA, which generally agreed with the CMC strategy and the proposed clinical development plan for Phase 1/2 trials for the treatment of neuroblastoma in pediatric patients aged 2-18. The company also plans to carry out further in vivo studies to explore SACT-1's efficacy against other cancer types, including colorectal cancer, leukemia, and lymphoma, to maximize its potential.

The timing and scope of advancing both ALS-4 Phase 2 clinical trials and SACT-1 Phase 1/2 trials are contingent upon securing appropriate collaborative partnerships and adequate funding resources. The company is actively seeking strategic collaborators who can provide both financial support and clinical expertise to advance these therapeutic programs. Aptorum anticipates submitting the INDs for ALS-4 by 2027 and commencing Phase 2 trials shortly thereafter, contingent on funding.

Regarding operational outlook, the company has adjusted its employment model, shifting from direct employment to outsourcing key functions, including research and development and back-office operations. This strategy aims for greater focus and flexibility. The company has also taken actions to remediate a material weakness in internal control over financial reporting, which was the lack of dedicated resources for finance and accounting functions and U.S. GAAP-compliant financial statement preparation. Remediation efforts include providing staff training, implementing a new accounting system, and establishing clear roles and responsibilities. However, management assessed that this deficiency still existed as of December 31, 2025.

Planned capital allocation includes funding patent costs from cash and restricted cash. The company intends to seek additional funding through equity offerings, debt financings, collaborations, licensing arrangements, strategic alliances, and marketing or distribution arrangements. The company's ability to complete the full clinical development, manufacturing, and launch of its drug candidates will likely require funding beyond its existing cash.

Structural headwinds and execution risks explicitly flagged by management include the inherent long, expensive, and uncertain process of preclinical and clinical drug development, with a high failure rate. The company currently does not generate revenue from product sales and may never become profitable without raising more capital. Difficulties in enrolling patients in clinical trials, failure to demonstrate safety and efficacy to regulatory authorities, and undesirable adverse events could delay or prevent regulatory approval. The company also faces risks related to intellectual property protection, reliance on unrelated parties for discovery, preclinical studies, clinical trials, and manufacturing, and the need to increase the size and capabilities of its organization to manage growth. Geopolitical and regulatory factors, particularly those related to operating in Hong Kong and potential PRC government influence, are also identified as significant risks. The company's auditor has expressed substantial doubt about its ability to continue as a going concern due to recurring net losses and limited cash reserves. The proposed merger with DiamiR is subject to various closing conditions, including Aptorum maintaining an aggregate amount of unrestricted cash and cash equivalents of not less than $2,260,000 ¹⁵ and working capital of not less than $1,644,000 ¹⁶, and failure to consummate the merger could adversely affect Aptorum's share price and operations.

Aptorum Group faces several material risks, including the fundamental challenge of not generating revenue from product sales and the uncertainty of ever achieving profitability, which is contingent on securing additional capital through financings, for which there is no guarantee. The preclinical and clinical development process for drug candidates is lengthy, expensive, and inherently unpredictable, with a high failure rate, and management retains discretion to terminate projects at any stage. The company relies heavily on the success of its Lead Projects, ALS-4 and SACT-1, and if it cannot license, sublicense, sell, or commercialize these candidates, or experiences significant delays, its business will be materially harmed. Regulatory approval processes by authorities like the FDA, NMPA, EMA, and Health Canada are time-consuming and unpredictable, and drug candidates may cause undesirable adverse events, leading to delays, denials, or restrictive labels. The company's intellectual property portfolio, largely comprising pending patent applications, may not result in granted patents, or issued patents may be challenged, diminishing their value and competitive advantage. Reliance on unrelated parties for discovery, preclinical studies, clinical trials, and manufacturing exposes the company to risks if these parties fail to meet contractual duties, deadlines, or quality standards. Operational risks include the need to increase organizational size and capabilities, potential difficulties in managing growth, and the risk that future collaborations or acquisitions may not realize anticipated benefits or may dilute shareholders. The company is exposed to risks associated with its computer hardware, network security, and data storage, as well as business disruptions from natural or man-made disasters. Furthermore, the company's operations in Hong Kong are subject to political and legal developments in the region, including potential changes in the economic, political, and legal environment, and the possibility of increased oversight and control by the PRC government, which could materially and adversely affect its business, financial condition, and results of operations. The company's auditor has expressed substantial doubt about its ability to continue as a going concern due to recurring net losses and limited cash reserves. The ongoing merger with DiamiR carries risks, including the possibility of non-consummation, which could lead to significant expenses, distraction of management, and potential delisting from Nasdaq. If the merger is terminated for reasons other than DiamiR's breach, Aptorum may be required to pay DiamiR a termination fee equal to the higher of 70% of its cash as of the termination date or $2,000,000 ¹⁷. As of December 31, 2025, Aptorum has approximately $3.5 million in cash ¹⁸ and current assets of approximately $3.6 million ¹⁹, and must maintain an aggregate of unrestricted cash and cash equivalents of not less than $2,260,000 ²⁰ and working capital of not less than $1,644,000 ²¹ at the closing date of the merger.

Management's message to shareholders emphasizes the company's dedication to the discovery, development, and commercialization of therapeutic assets for diseases with unmet medical needs, particularly in oncology and infectious diseases, with a strategic focus on products that may attain orphan drug designation. The company has streamlined operations by terminating clinic services and suspending non-lead R&D projects to optimize resource allocation and focus on its Lead Projects, ALS-4 and SACT-1, which are considered to hold the most promise for commercial success and beneficial impact. Management explicitly states that the timing and scope of advancing both ALS-4 Phase 2 clinical trials and SACT-1 Phase 1/2 trials are contingent upon securing appropriate collaborative partnerships and adequate funding resources, and the company is actively seeking strategic collaborators who can provide both financial support and clinical expertise. The company anticipates submitting the INDs for ALS-4 by 2027 and commencing Phase 2 trials shortly thereafter, contingent on funding. Management acknowledges that if additional funds are needed, they will seek to raise them in the most effective way possible. The overall tone indicates a strategic pivot towards focused R&D and a reliance on external partnerships and future capital raises to advance its pipeline.